Zofin

Zofin or Organicell Flow is an unapproved treatment that has been used on a number of patients severely ill with long-lasting COVID-19 symptoms under a compassionate use authorization. Zofin is a biological product derived from the human amniotic fluid (HAF) donated from the births of healthy, newborn babies; it is administered by intravenous infusion.

Zofin is produced by the company Organicell which states that it "contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from amniotic stem and epithelial cells" including the proteins CD63, CD81, and CD9 in addition to high expression of CD133.

Theory
According to Organicell, pro-inflammatory cytokines believed to be targeted by Zofin include tumor necrosis factor (TNF), IL-6, and IL-8, and published research states that targeting these may "reduce the severity of symptoms associated with elevated immune response".

Risks and safety
Zofin has not yet been approved for use and clinical trials remain ongoing.

Risks, side effects and safety are largely unknown.

Costs and availability
Zofin is not yet an approved drug and availability is limited to special authorizations.

Learn more

 * Organicell reports positive results from compassionate use of Organicell Flow - Organicell
 * Clinical trial NCT04384445